The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
Identifieur interne : 004F77 ( PubMed/Curation ); précédent : 004F76; suivant : 004F78The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
Auteurs : R J Coleman [Royaume-Uni] ; K W Lange ; N P Quinn ; A E Loper ; J V Bondi ; M. Hichens ; S M Stahl ; C D MarsdenSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1989.
English descriptors
- KwdEn :
- Administration, Cutaneous, Adult, Antiparkinson Agents (antagonists & inhibitors), Antiparkinson Agents (pharmacokinetics), Dopamine Antagonists, Drug Administration Schedule, Drug Therapy, Combination, Humans, Levodopa (administration & dosage), Middle Aged, Motor Skills (drug effects), Oxazines (administration & dosage), Oxazines (pharmacokinetics), Parkinson Disease (blood), Parkinson Disease (drug therapy).
- MESH :
- chemical , administration & dosage : Levodopa, Oxazines.
- chemical , antagonists & inhibitors : Antiparkinson Agents.
- chemical , pharmacokinetics : Antiparkinson Agents, Oxazines.
- blood : Parkinson Disease.
- drug effects : Motor Skills.
- drug therapy : Parkinson Disease.
- Administration, Cutaneous, Adult, Dopamine Antagonists, Drug Administration Schedule, Drug Therapy, Combination, Humans, Middle Aged.
Abstract
(+)-4-Propyl-9-hydroxynaphthoxazine (+PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and "on-off" fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of +PHNO began to rise 4-6 h after patch application and reached a steady state by 24 h. The final plasma concentration of +PHNO was proportional to the area of skin covered.
DOI: 10.1002/mds.870040204
PubMed: 2733705
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004F77
Links to Exploration step
pubmed:2733705Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.</title><author><name sortKey="Coleman, R J" sort="Coleman, R J" uniqKey="Coleman R" first="R J" last="Coleman">R J Coleman</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Neurology, London, U.K.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, London</wicri:regionArea></affiliation></author><author><name sortKey="Lange, K W" sort="Lange, K W" uniqKey="Lange K" first="K W" last="Lange">K W Lange</name></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N P" last="Quinn">N P Quinn</name></author><author><name sortKey="Loper, A E" sort="Loper, A E" uniqKey="Loper A" first="A E" last="Loper">A E Loper</name></author><author><name sortKey="Bondi, J V" sort="Bondi, J V" uniqKey="Bondi J" first="J V" last="Bondi">J V Bondi</name></author><author><name sortKey="Hichens, M" sort="Hichens, M" uniqKey="Hichens M" first="M" last="Hichens">M. Hichens</name></author><author><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S M" last="Stahl">S M Stahl</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C D" last="Marsden">C D Marsden</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1989">1989</date><idno type="RBID">pubmed:2733705</idno><idno type="pmid">2733705</idno><idno type="doi">10.1002/mds.870040204</idno><idno type="wicri:Area/PubMed/Corpus">004F77</idno><idno type="wicri:Area/PubMed/Curation">004F77</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.</title><author><name sortKey="Coleman, R J" sort="Coleman, R J" uniqKey="Coleman R" first="R J" last="Coleman">R J Coleman</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Neurology, London, U.K.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Neurology, London</wicri:regionArea></affiliation></author><author><name sortKey="Lange, K W" sort="Lange, K W" uniqKey="Lange K" first="K W" last="Lange">K W Lange</name></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N P" last="Quinn">N P Quinn</name></author><author><name sortKey="Loper, A E" sort="Loper, A E" uniqKey="Loper A" first="A E" last="Loper">A E Loper</name></author><author><name sortKey="Bondi, J V" sort="Bondi, J V" uniqKey="Bondi J" first="J V" last="Bondi">J V Bondi</name></author><author><name sortKey="Hichens, M" sort="Hichens, M" uniqKey="Hichens M" first="M" last="Hichens">M. Hichens</name></author><author><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S M" last="Stahl">S M Stahl</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C D" last="Marsden">C D Marsden</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1989" type="published">1989</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Antiparkinson Agents (antagonists & inhibitors)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Dopamine Antagonists</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Oxazines (administration & dosage)</term><term>Oxazines (pharmacokinetics)</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Levodopa</term><term>Oxazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Oxazines</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Dopamine Antagonists</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">(+)-4-Propyl-9-hydroxynaphthoxazine (+PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and "on-off" fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of +PHNO began to rise 4-6 h after patch application and reached a steady state by 24 h. The final plasma concentration of +PHNO was proportional to the area of skin covered.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">2733705</PMID><DateCreated><Year>1989</Year><Month>07</Month><Day>17</Day></DateCreated><DateCompleted><Year>1989</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.</ArticleTitle><Pagination><MedlinePgn>129-38</MedlinePgn></Pagination><Abstract><AbstractText>(+)-4-Propyl-9-hydroxynaphthoxazine (+PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and "on-off" fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of +PHNO began to rise 4-6 h after patch application and reached a steady state by 24 h. The final plasma concentration of +PHNO was proportional to the area of skin covered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Institute of Neurology, London, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>K W</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>N P</ForeName><Initials>NP</Initials></Author><Author ValidYN="Y"><LastName>Loper</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Bondi</LastName><ForeName>J V</ForeName><Initials>JV</Initials></Author><Author ValidYN="Y"><LastName>Hichens</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stahl</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Marsden</LastName><ForeName>C D</ForeName><Initials>CD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010078">Oxazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>22Z7E0X6OF</RegistryNumber><NameOfSubstance UI="C042631">naxagolide</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000279">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000037">antagonists & inhibitors</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018492">Dopamine Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009048">Motor Skills</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010078">Oxazines</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2733705</ArticleId><ArticleId IdType="doi">10.1002/mds.870040204</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F77 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004F77 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:2733705
|texte= The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:2733705" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |